Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041694 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL16115787 | 0.84 | GAA (0.47) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL16115788 | 0.84 | GAA (0.47) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL23539268 | 0.84 | GAA (0.47) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL23691222 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL23554205 | 0.79 | FADS1 (0.43) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL8657109 | 0.77 | MAPT (0.64) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL359987 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL359986 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9AMAPTNPC1MEN1 | |
| SCHEMBL14916611 | 0.76 | RAB9A (0.44) | SMN1; SMN2RAB9AMAPTNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115279741-A | 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders | 医肯纳肿瘤学公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127301-A1 | 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | SMN1; SMN2 4815/4885RAB9A 4470/4885MAPT 4673/4885 |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | SMN1; SMN2 4815/4885RAB9A 4470/4885MAPT 4673/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | SMN1; SMN2 4815/4885RAB9A 4470/4885MAPT 4673/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | SMN1; SMN2 4815/4885RAB9A 4470/4885MAPT 4673/4885 |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | SMN1; SMN2 4815/4885RAB9A 4470/4885MAPT 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.